BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26637908)

  • 1. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
    Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
    Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
    Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
    Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
    Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
    Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials.
    Kong L; Hu C; Niu X; Zhang Y; Guo Y; Tham IW; Lu JJ
    Cancer; 2013 Dec; 119(23):4111-8. PubMed ID: 24037893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
    Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
    Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
    Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
    Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.